Matches in SemOpenAlex for { <https://semopenalex.org/work/W86691354> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W86691354 endingPage "8091" @default.
- W86691354 startingPage "8091" @default.
- W86691354 abstract "8091 Background: A significant proportion of cancer patients receiving chemotherapy will present with or develop anemia. The cause of this anemia is often the inflammatory cytokine-mediated anemia of chronic disease associated with cancer and/or chemotherapy. We are currently performing a trial in anemic cancer patients on chemotherapy being treated with EPO to see if no iron, oral iron, or iv iron improves the Hb response. While this trial is still ongoing, we report here the initial anemia screening parameters for all patients considered for study. Methods: After giving informed consent, patients starting a cycle of chemotherapy were screened. Samples were sent to a central laboratory for screening if a recent Hb was <11g/dL, the pt was eligible for EPO therapy, and had not been treated with EPO during the preceding 30 days. Results: Of 261 patients screened (174 female), overall 44 pts (17%) had ferritin <100ng/mL, and 154 pts (59%) had transferrin (TSAT) < 20%. Among pts with ferritin <100ng/ml, 77% also had TSAT < 20%. While 216 pts (83%) had ferritin >100ng/mL, 120 of these (46% of all pts) also had TSAT <20%. Seventy pts (27%) had content of reticulocyte hemoglobin (CHR) < 32 g/dL. No pts had red blood cell folate < 93ng/mL. Of 5 pts with low B12, only one had elevated MCV. Conclusions: Our results indicate a surprising prevalence of B12 and/or Iron deficiency in anemic cancer patients presenting for EPO therapy. Possible iron deficiency was indicated by either TSAT <20 % (which may coexist with an elevated ferritin), ferritin of < 100ng/ml and/or CHR < 32 g/dL. A small but significant proportion of anemic cancer pts presenting for EPO therapy may have B12 or iron deficiency. A basic work up to rule out treatable causes of anemia such as B12 or iron deficiency should be performed. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Watson Laboratories Watson Pharma" @default.
- W86691354 created "2016-06-24" @default.
- W86691354 creator A5012507181 @default.
- W86691354 creator A5027452855 @default.
- W86691354 date "2004-07-15" @default.
- W86691354 modified "2023-10-16" @default.
- W86691354 title "Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alpha (EPO) therapy" @default.
- W86691354 doi "https://doi.org/10.1200/jco.2004.22.90140.8091" @default.
- W86691354 hasPublicationYear "2004" @default.
- W86691354 type Work @default.
- W86691354 sameAs 86691354 @default.
- W86691354 citedByCount "5" @default.
- W86691354 crossrefType "journal-article" @default.
- W86691354 hasAuthorship W86691354A5012507181 @default.
- W86691354 hasAuthorship W86691354A5027452855 @default.
- W86691354 hasConcept C121608353 @default.
- W86691354 hasConcept C126322002 @default.
- W86691354 hasConcept C2775989426 @default.
- W86691354 hasConcept C2776694085 @default.
- W86691354 hasConcept C2777417653 @default.
- W86691354 hasConcept C2778248108 @default.
- W86691354 hasConcept C2778319317 @default.
- W86691354 hasConcept C2778917026 @default.
- W86691354 hasConcept C71924100 @default.
- W86691354 hasConcept C90924648 @default.
- W86691354 hasConceptScore W86691354C121608353 @default.
- W86691354 hasConceptScore W86691354C126322002 @default.
- W86691354 hasConceptScore W86691354C2775989426 @default.
- W86691354 hasConceptScore W86691354C2776694085 @default.
- W86691354 hasConceptScore W86691354C2777417653 @default.
- W86691354 hasConceptScore W86691354C2778248108 @default.
- W86691354 hasConceptScore W86691354C2778319317 @default.
- W86691354 hasConceptScore W86691354C2778917026 @default.
- W86691354 hasConceptScore W86691354C71924100 @default.
- W86691354 hasConceptScore W86691354C90924648 @default.
- W86691354 hasIssue "14_suppl" @default.
- W86691354 hasLocation W866913541 @default.
- W86691354 hasOpenAccess W86691354 @default.
- W86691354 hasPrimaryLocation W866913541 @default.
- W86691354 hasRelatedWork W1840260122 @default.
- W86691354 hasRelatedWork W2077070367 @default.
- W86691354 hasRelatedWork W2342849232 @default.
- W86691354 hasRelatedWork W2395909070 @default.
- W86691354 hasRelatedWork W2799395871 @default.
- W86691354 hasRelatedWork W2883390505 @default.
- W86691354 hasRelatedWork W2910240063 @default.
- W86691354 hasRelatedWork W2921075033 @default.
- W86691354 hasRelatedWork W4292831968 @default.
- W86691354 hasRelatedWork W4376647680 @default.
- W86691354 hasVolume "22" @default.
- W86691354 isParatext "false" @default.
- W86691354 isRetracted "false" @default.
- W86691354 magId "86691354" @default.
- W86691354 workType "article" @default.